Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.